MONTREAL, June 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of IntelGenx Technologies Corp.) (OTCQB: IGXT; TSX: IGX), was granted protection pursuant to an...
MONTREAL, May 28, 2024 (GLOBE NEWSWIRE) -- As previously announced on May 17, 2024, IntelGenx Technologies Corp. (the Company or IntelGenx) (OCTQB: IGXT; TSX: IGX), a leading drug delivery...
MONTREAL, May 17, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the Company or IntelGenx) (OCTQB: IGXT; TSX: IGX), a leading drug delivery company focused on the development and...
SAINT LAURENT, Quebec, May 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the Company or IntelGenx) announces that, at the annual meeting of shareholders of...
SAINT LAURENT, Quebec, April 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the Company or IntelGenx) today announced that its co-developer, Chemo Research SL, through its...
IntelGenx Enters Into a Third Amended Agreement atai Life Sciences
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With ATAI Life
Studies Validate Advantages Administering Drugs to Pets via IntelGenx’s VetaFilm